View Future GrowthDx & Vx 過去の業績過去 基準チェック /06Dx & Vxの収益は年間平均-41.9%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間15.2% 18%割合で 増加しています。主要情報-41.88%収益成長率-31.81%EPS成長率Biotechs 業界の成長11.70%収益成長率17.99%株主資本利益率-32.90%ネット・マージン-103.14%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • Mar 23Full year 2023 earnings released: ₩929 loss per share (vs ₩47.45 loss in FY 2022)Full year 2023 results: ₩929 loss per share (further deteriorated from ₩47.45 loss in FY 2022). Revenue: ₩46.7b (up 45% from FY 2022). Net loss: ₩27.5b (loss widened ₩26.1b from FY 2022).すべての更新を表示Recent updatesお知らせ • Mar 17Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South KoreaNew Risk • Jan 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding).New Risk • Dec 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩25b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years.お知らせ • Dec 23Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering.Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 49,210,000 Transaction Features: Subsequent Direct ListingNew Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩111.5b market cap, or US$75.4m).分析記事 • Dec 18The Market Doesn't Like What It Sees From Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues YetDx & Vx Co., Ltd.'s ( KOSDAQ:180400 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...New Risk • Nov 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -₩3.2b This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩88.4b market cap, or US$60.2m).分析記事 • Aug 20There's No Escaping Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Muted Revenues Despite A 28% Share Price RiseKOSDAQ:A180400 1 Year Share Price vs Fair Value Explore Dx & Vx's Fair Values from the Community and select yours Dx...分析記事 • Aug 18We Think Dx & Vx (KOSDAQ:180400) Has A Fair Chunk Of DebtKOSDAQ:A180400 1 Year Share Price vs Fair Value Explore Dx & Vx's Fair Values from the Community and select yours Some...New Risk • Jul 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Earnings have declined by 40% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩132.4b market cap, or US$95.9m).お知らせ • May 30Dx&Vx Accelerates Development of Universal COVID-19 VaccineDx&Vx (DXVX) has officially announced the acceleration of its development program for a universal COVID-19 vaccine, following the recent acquisition of related technology. Designed to provide immunity against both current and future variants of the coronavirus, this next-generation vaccine is drawing global attention amid a new wave of COVID-19 cases worldwide. Global health organizations, including the WHO, have raised concerns about rising COVID-19 cases in parts of Europe, Asia, and North America. These warnings have highlighted the urgent need for more robust and lasting immune solutions against evolving virus variants. Currently, DXVX is advancing through the regulatory procedures necessary to initiate Phase 2 clinical trials in South Korea, the U.S., and Southeast Asia. After successfully completing Phase 1 trials in the U.S. and South Africa, the company is preparing its Investigational New Drug (IND) applications for global Phase 2 studies.お知らせ • Mar 12Dx & Vx Co., Ltd., Annual General Meeting, Mar 28, 2025Dx & Vx Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea分析記事 • Feb 14Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 32% LowerThe Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩65.0b market cap, or US$45.1m).分析記事 • Feb 12Is Dx & Vx (KOSDAQ:180400) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Dec 05Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 28%The Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩93.1b market cap, or US$66.7m).分析記事 • Oct 21Positive Sentiment Still Eludes Dx & Vx Co., Ltd. (KOSDAQ:180400) Following 27% Share Price SlumpDx & Vx Co., Ltd. ( KOSDAQ:180400 ) shareholders that were waiting for something to happen have been dealt a blow with...お知らせ • Oct 04Dx & Vx Co., Ltd. (KOSDAQ:A180400) agreed to acquire remaining 37% stake in Avixgen, Inc. for KRW 4.7 billion.Dx & Vx Co., Ltd. (KOSDAQ:A180400) agreed to acquire remaining 37% stake in Avixgen, Inc. for KRW 4.7 billion on October 2, 2024. The consideration consists of 1.7 million common equity of Dx & Vx Co., Ltd. at a ratio of 0.290319 per common equity of Avixgen, Inc. The merger agreement is expected to signed on October 4, 2024. The expected completion of the transaction is December 17, 2024.New Risk • Oct 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩131.4b market cap, or US$98.6m).お知らせ • Sep 13Dx & Vx Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 42.37 billion.Dx & Vx Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 42.37 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 18,385,983 Price\Range: KRW 2230 Discount Per Security: KRW 44.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 614,017 Price\Range: KRW 2230 Discount Per Security: KRW 44.6 Transaction Features: Rights OfferingNew Risk • Aug 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩111.4b market cap, or US$83.4m).お知らせ • Jul 19DX&VX Is on Track and Accelerating the Development of Oral Obesity TreatmentDX&VX, which is gaining attention for developing an oral GLP-1 obesity treatment. The company is accelerating the optimization of new drug candidates. GLP-1 (glucagon-like peptide-1), an oral obesity treatment drug being developed by DX&VX, is a hormone that induces weight loss by suppressing appetite and increasing satiety to treat obesity. DX&VX researchers have developed organic compounds that can be taken orally once a day instead of through injections. While obesity treatment drug developers are conducting clinical trials for new oral GLP-1 organic compound drugs, the importance of this field is expanding day by day. To date, DX&VX has secured excellent candidate substances based on its AI-based innovative new drug design technology, and plans to submit patents for at least two more substances within this year. This research outcome is receiving significant attention from the industry and many pharmaceutical companies, both domestically and internationally, with some companies exploring the possibility of cooperation with DX&VX. Based on these achievements, DX&VX is expected to further accelerate the development of oral GLP-1 obesity treatments by utilizing various options such as early licensing out, global joint clinical trials, and research funding investment. As additional research results and patent applications continue, the obesity treatment drug being developed byDX&VX is expected to have stronger market competitiveness in the future.分析記事 • Jul 15Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 39% LowerUnfortunately for some shareholders, the Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has dived 39% in the last...分析記事 • May 31Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 37%The Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...New Risk • May 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Market cap is less than US$100m (₩84.6b market cap, or US$61.5m).New Risk • May 29New major risk - Revenue and earnings growthEarnings have declined by 9.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Market cap is less than US$100m (₩123.9b market cap, or US$90.8m).Reported Earnings • Mar 23Full year 2023 earnings released: ₩929 loss per share (vs ₩47.45 loss in FY 2022)Full year 2023 results: ₩929 loss per share (further deteriorated from ₩47.45 loss in FY 2022). Revenue: ₩46.7b (up 45% from FY 2022). Net loss: ₩27.5b (loss widened ₩26.1b from FY 2022).分析記事 • Mar 18Investors Give Dx & Vx Co., Ltd. (KOSDAQ:180400) Shares A 25% HidingTo the annoyance of some shareholders, Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) shares are down a considerable 25% in the...分析記事 • Mar 08Dx & Vx (KOSDAQ:180400) Is Carrying A Fair Bit Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Oct 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).New Risk • Jun 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).お知らせ • Jun 15Dx & Vx Co., Ltd. announced that it has received KRW 9.223311402 billion in funding from Renaissance Asset Management and other investorsOn June 14, 2023, Dx & Vx Co., Ltd. closed the transaction.お知らせ • May 25Dx & Vx Co., Ltd. (KOSDAQ:A180400) acquired Avixgen, IncDx & Vx Co., Ltd. (KOSDAQ:A180400) acquired Avixgen, Inc. recently.お知らせ • May 17+ 1 more updateDxVx Appoints Kevin Kwon as New PresidentDxVx announced on May 16, 2023, the board of directors appointed Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president. The new president, Kevin Kwon, holds a bachelor's and master's degree in applied bio-chemistry from Seoul National University, as well as a doctorate in management of technology from Korea University. He worked at the LG Chemical Biotech Research Institute and Regulatory Affairs (RA) Team in the LG Life Science. At Hanmi Pharm.Co.,Ltd, he served as the head of the global business division. He was a key person in global pharmaceutical business operations including global RA, overseas business development, overseas sales, clinical trials for new drug and licensing activities. In his career, he served as a joint professor at the Korea University Engineering Graduate School, an advisor for Korea Innovative Medicine Consortium (KimCo), an advisor for the formulation of bio similar regulations for the Ministry of Food and Drug Safety, a delegate for opening global markets at the Korea Health Industry Development Institute, and a professor for academic and business cooperation at Catholic University. Currently, he serves as a member of the special committee for global expansion at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. New president Kevin Kwon will be appointed as a board director from a shareholders' meeting. The former CEO, Sang Tae Park, has been nominated for the board director at Avixgen. In his new role, he intends to continue to make contributions to the company's growth by taking the lead in advancing the pipeline for new drugs and establishing a presence in the North American market.Board Change • Apr 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.収支内訳Dx & Vx の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A180400 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Mar 2628,483-29,37715,4188,53631 Dec 2529,357-30,28517,9188,62630 Sep 2529,468-51,80623,10010,34730 Jun 2531,115-52,15521,61111,48931 Mar 2531,144-48,55716,96110,64931 Dec 2433,947-48,15315,62510,27930 Sep 2434,564-36,68816,7758,38230 Jun 2437,677-31,92317,0216,30831 Mar 2442,690-34,65121,0974,75231 Dec 2341,244-30,19218,7353,33130 Sep 2343,432-16,84413,9072,30230 Jun 2341,721-11,79612,00892731 Mar 2335,144-4,2687,0141,09731 Dec 2232,184-1,3706,00179231 Mar 2211,463-5,9873,56381831 Dec 217,470-6,1253,43664730 Sep 218,864-3,5993,0191,82330 Jun 218,804-3,3533,0821,82331 Mar 218,170-4,1663,3051,82331 Dec 207,696-6,4034,3221,82330 Sep 206,385-12,7115,20484930 Jun 206,387-13,5476,07784931 Mar 205,717-15,2305,86784931 Dec 195,753-17,0866,35784930 Sep 195,758-10,3817,33074530 Jun 195,717-14,0776,60574531 Mar 195,599-13,3327,20257931 Dec 185,305-11,3486,12074530 Sep 184,947-12,7796,70719330 Jun 184,703-7,2925,60636231 Dec 174,670-3,7433,046615質の高い収益: A180400は現在利益が出ていません。利益率の向上: A180400は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A180400は利益が出ておらず、過去 5 年間で損失は年間41.9%の割合で増加しています。成長の加速: A180400の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: A180400は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 22.6% ) と比較することは困難です。株主資本利益率高いROE: A180400は現在利益が出ていないため、自己資本利益率 ( -32.9% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/05 18:06終値2026/08/05 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Dx & Vx Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Mar 23Full year 2023 earnings released: ₩929 loss per share (vs ₩47.45 loss in FY 2022)Full year 2023 results: ₩929 loss per share (further deteriorated from ₩47.45 loss in FY 2022). Revenue: ₩46.7b (up 45% from FY 2022). Net loss: ₩27.5b (loss widened ₩26.1b from FY 2022).
お知らせ • Mar 17Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
New Risk • Jan 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding).
New Risk • Dec 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩25b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years.
お知らせ • Dec 23Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering.Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 49,210,000 Transaction Features: Subsequent Direct Listing
New Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩111.5b market cap, or US$75.4m).
分析記事 • Dec 18The Market Doesn't Like What It Sees From Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues YetDx & Vx Co., Ltd.'s ( KOSDAQ:180400 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...
New Risk • Nov 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -₩3.2b This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩88.4b market cap, or US$60.2m).
分析記事 • Aug 20There's No Escaping Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Muted Revenues Despite A 28% Share Price RiseKOSDAQ:A180400 1 Year Share Price vs Fair Value Explore Dx & Vx's Fair Values from the Community and select yours Dx...
分析記事 • Aug 18We Think Dx & Vx (KOSDAQ:180400) Has A Fair Chunk Of DebtKOSDAQ:A180400 1 Year Share Price vs Fair Value Explore Dx & Vx's Fair Values from the Community and select yours Some...
New Risk • Jul 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Earnings have declined by 40% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩132.4b market cap, or US$95.9m).
お知らせ • May 30Dx&Vx Accelerates Development of Universal COVID-19 VaccineDx&Vx (DXVX) has officially announced the acceleration of its development program for a universal COVID-19 vaccine, following the recent acquisition of related technology. Designed to provide immunity against both current and future variants of the coronavirus, this next-generation vaccine is drawing global attention amid a new wave of COVID-19 cases worldwide. Global health organizations, including the WHO, have raised concerns about rising COVID-19 cases in parts of Europe, Asia, and North America. These warnings have highlighted the urgent need for more robust and lasting immune solutions against evolving virus variants. Currently, DXVX is advancing through the regulatory procedures necessary to initiate Phase 2 clinical trials in South Korea, the U.S., and Southeast Asia. After successfully completing Phase 1 trials in the U.S. and South Africa, the company is preparing its Investigational New Drug (IND) applications for global Phase 2 studies.
お知らせ • Mar 12Dx & Vx Co., Ltd., Annual General Meeting, Mar 28, 2025Dx & Vx Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
分析記事 • Feb 14Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 32% LowerThe Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...
New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩65.0b market cap, or US$45.1m).
分析記事 • Feb 12Is Dx & Vx (KOSDAQ:180400) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Dec 05Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 28%The Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...
New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩93.1b market cap, or US$66.7m).
分析記事 • Oct 21Positive Sentiment Still Eludes Dx & Vx Co., Ltd. (KOSDAQ:180400) Following 27% Share Price SlumpDx & Vx Co., Ltd. ( KOSDAQ:180400 ) shareholders that were waiting for something to happen have been dealt a blow with...
お知らせ • Oct 04Dx & Vx Co., Ltd. (KOSDAQ:A180400) agreed to acquire remaining 37% stake in Avixgen, Inc. for KRW 4.7 billion.Dx & Vx Co., Ltd. (KOSDAQ:A180400) agreed to acquire remaining 37% stake in Avixgen, Inc. for KRW 4.7 billion on October 2, 2024. The consideration consists of 1.7 million common equity of Dx & Vx Co., Ltd. at a ratio of 0.290319 per common equity of Avixgen, Inc. The merger agreement is expected to signed on October 4, 2024. The expected completion of the transaction is December 17, 2024.
New Risk • Oct 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩131.4b market cap, or US$98.6m).
お知らせ • Sep 13Dx & Vx Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 42.37 billion.Dx & Vx Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 42.37 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 18,385,983 Price\Range: KRW 2230 Discount Per Security: KRW 44.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 614,017 Price\Range: KRW 2230 Discount Per Security: KRW 44.6 Transaction Features: Rights Offering
New Risk • Aug 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩111.4b market cap, or US$83.4m).
お知らせ • Jul 19DX&VX Is on Track and Accelerating the Development of Oral Obesity TreatmentDX&VX, which is gaining attention for developing an oral GLP-1 obesity treatment. The company is accelerating the optimization of new drug candidates. GLP-1 (glucagon-like peptide-1), an oral obesity treatment drug being developed by DX&VX, is a hormone that induces weight loss by suppressing appetite and increasing satiety to treat obesity. DX&VX researchers have developed organic compounds that can be taken orally once a day instead of through injections. While obesity treatment drug developers are conducting clinical trials for new oral GLP-1 organic compound drugs, the importance of this field is expanding day by day. To date, DX&VX has secured excellent candidate substances based on its AI-based innovative new drug design technology, and plans to submit patents for at least two more substances within this year. This research outcome is receiving significant attention from the industry and many pharmaceutical companies, both domestically and internationally, with some companies exploring the possibility of cooperation with DX&VX. Based on these achievements, DX&VX is expected to further accelerate the development of oral GLP-1 obesity treatments by utilizing various options such as early licensing out, global joint clinical trials, and research funding investment. As additional research results and patent applications continue, the obesity treatment drug being developed byDX&VX is expected to have stronger market competitiveness in the future.
分析記事 • Jul 15Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 39% LowerUnfortunately for some shareholders, the Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has dived 39% in the last...
分析記事 • May 31Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 37%The Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...
New Risk • May 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Market cap is less than US$100m (₩84.6b market cap, or US$61.5m).
New Risk • May 29New major risk - Revenue and earnings growthEarnings have declined by 9.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Market cap is less than US$100m (₩123.9b market cap, or US$90.8m).
Reported Earnings • Mar 23Full year 2023 earnings released: ₩929 loss per share (vs ₩47.45 loss in FY 2022)Full year 2023 results: ₩929 loss per share (further deteriorated from ₩47.45 loss in FY 2022). Revenue: ₩46.7b (up 45% from FY 2022). Net loss: ₩27.5b (loss widened ₩26.1b from FY 2022).
分析記事 • Mar 18Investors Give Dx & Vx Co., Ltd. (KOSDAQ:180400) Shares A 25% HidingTo the annoyance of some shareholders, Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) shares are down a considerable 25% in the...
分析記事 • Mar 08Dx & Vx (KOSDAQ:180400) Is Carrying A Fair Bit Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Oct 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).
New Risk • Jun 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).
お知らせ • Jun 15Dx & Vx Co., Ltd. announced that it has received KRW 9.223311402 billion in funding from Renaissance Asset Management and other investorsOn June 14, 2023, Dx & Vx Co., Ltd. closed the transaction.
お知らせ • May 25Dx & Vx Co., Ltd. (KOSDAQ:A180400) acquired Avixgen, IncDx & Vx Co., Ltd. (KOSDAQ:A180400) acquired Avixgen, Inc. recently.
お知らせ • May 17+ 1 more updateDxVx Appoints Kevin Kwon as New PresidentDxVx announced on May 16, 2023, the board of directors appointed Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president. The new president, Kevin Kwon, holds a bachelor's and master's degree in applied bio-chemistry from Seoul National University, as well as a doctorate in management of technology from Korea University. He worked at the LG Chemical Biotech Research Institute and Regulatory Affairs (RA) Team in the LG Life Science. At Hanmi Pharm.Co.,Ltd, he served as the head of the global business division. He was a key person in global pharmaceutical business operations including global RA, overseas business development, overseas sales, clinical trials for new drug and licensing activities. In his career, he served as a joint professor at the Korea University Engineering Graduate School, an advisor for Korea Innovative Medicine Consortium (KimCo), an advisor for the formulation of bio similar regulations for the Ministry of Food and Drug Safety, a delegate for opening global markets at the Korea Health Industry Development Institute, and a professor for academic and business cooperation at Catholic University. Currently, he serves as a member of the special committee for global expansion at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. New president Kevin Kwon will be appointed as a board director from a shareholders' meeting. The former CEO, Sang Tae Park, has been nominated for the board director at Avixgen. In his new role, he intends to continue to make contributions to the company's growth by taking the lead in advancing the pipeline for new drugs and establishing a presence in the North American market.
Board Change • Apr 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.